TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
The approval is good for CSL, and better for Uniqure.
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
As the company pulls Blenrep, questions about its future will only intensify.
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.